Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 1, 2011, Pages 7-13

  Menon, Vandana ^a   Rudym, Darya ^a   Chandra, Priya ^a   Miskulin, Dana ^a   Perrone, Ronald ^a   Sarnak, Mark ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; PROSTAGLANDIN F2 ALPHA; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PROSTAGLANDIN BLOOD LEVEL; PROTEIN BLOOD LEVEL;

ADULT; C-REACTIVE PROTEIN; DINOPROST; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; MIDDLE AGED; OXIDATIVE STRESS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SUPEROXIDE DISMUTASE;

EID: 79251519339     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04140510     Document Type: Article

References (27)

1. Perrone RD, Ruthazer R, Terrin NC: Survival after endstage renal disease in autosomal dominant polycystic kidney disease: Contribution of extrarenal complications to mortality. Am J Kidney Dis 38: 777-784, 2001
2. Fick GM, Johnson AM, Hammond WS, Gabow PA: Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5: 2048-2056, 1995
3. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. The Lancet 369: 1287-1301, 2007
4. Gabow PA, Chapman AB, Johnson AM, Tangel DJ, Duley IT, Kaehny WD, Manco-Johnson M, Schrier RW: Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 38: 1177-1180, 1990
5. Gonzalo A, Gallego A, Rivera M, Orte L, Ortuno J: Influence of hypertension on early renal insufficiency in autosomal dominant polycystic kidney disease. Nephron 72: 225-230, 1996 (Pubitemid 26035381)
6. Bardaji A, Martinez-Vea A, Valero A, Gutierrez C, Garcia C, Ridao C, Oliver JA, Richart C: Cardiac involvement in autosomal-dominant polycystic kidney disease: A hypertensive heart disease. Clin Nephrol 56: 211-220, 2001
7. Cowley BD Jr., Ricardo SD, Nagao S, Diamond JR: Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int 60: 2087-2096, 2001
8. Maser RL, Vassmer D, Magenheimer BS, Calvet JP: Oxidant stress and reduced antioxidant enzyme protection in polycystic kidney disease. J Am Soc Nephrol 13: 991-999, 2002
9. Merta M, Tesar V, Zima T, Jirsa M, Rysava R, Zabka J: Cytokine profile in autosomal dominant polycystic kidney disease. Biochem Mol Biol Int 41: 619-624, 1997
10. Vareesangthip K, Tong P, Wilkinson R, Thomas TH: Insulin resistance in adult polycystic kidney disease. Kidney Int 52: 503-508, 1997
11. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53: 1343-1347, 1998
12. Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miler JP, Miskulin DC, Oskoui FR, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW: The HALT polycystic kidney disease trials: Design and implementation. Clin J Am Soc Nephrol 5: 102-109, 2010
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985
15. Zheng D, Wolfe M, Cowley BD Jr., Wallace DP, Yamaguchi T, Grantham JJ: Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 14: 2588-2595, 2003
16. Li X, Magenheimer BS, Xia S, Johnson T, Wallace DP, Calvet JP, Li R: A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med 14: 863-868, 2008
17. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B: Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 39: 954-960, 1991
18. Grantham JJ: Mechanisms of progression in autosomal dominant polycystic kidney disease. Kidney Int Suppl 63: S93-S97, 1997
19. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002
20. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB: Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 59: 1960-1966, 2001
21. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, Zingraff J, Verger C, Jingers P, Descamps-Latscha B: Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 21: 845-853, 1996
22. Morrow JD, Frei B, Longmire AW, Gaziano M, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ: Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 332: 1198-1203, 1995
23. Miao L, St. Clair DK: Regulation of superoxide dismutase genes: Implications in disease. Free Radic Biol and Med 47: 344-356, 2009
24. Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q, Wilcox CS: Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 51: 184-191, 2008
25. Harrap SB, Davies DL, Macnicol AM, Dominiczak AF, Fraser R, Wright AF, Watson ML, Briggs JD: Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 40: 501-508, 1991
26. Tanifuji C, Suzuki Y, Geot WM, Horikoshi S, Takahashi H, Tomino Y: Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys. Kidney Blood Press Res 32: 239-249, 2009
27. van Dijk MA, Kamper AM, van Veen S, Souverijn JHM, Blauw GJ: Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 16: 2152-2157, 2001